Time For Similares To Exit The Drug Market?

Generic drug market growth in Mexico has been hindered by regulatory issues in, but recent developments indicate the government may be achieving the phasing out of similares, which are non-bioequivalent copy drugs. Their presence in the Mexican drug market is problematic - largely because they are weakly regulated and therefore likely to be unsafe, while also being cheaper than their patented or generic counterparts.

To read the full article, please choose one of the following options: